临床试验进展 - 完成了全球关键性第三期EFZO-FIT™临床试验的患者入组，共268名肺部肉芽肿患者[5] - 正在进行EFZO-CONNECT™II期临床试验，评估efzofitimod在系统性硬化相关间质性肺疾病患者中的疗效、安全性和耐受性[6][7] - 完成EFZO-FIT™III期试验预计于2025年第三季度公布[5] - EFZO-CONNECT™II期试验预计于2025年第二季度公布中期数据[7] - 公司正在开展一项针对完成EFZO-FIT™试验的患者的个人患者扩展获取计划[5] 财务状况 - 截至2024年6月30日，公司现金、现金等价物、受限现金和投资总额为8.14亿美元[8] - 第二季度研发费用为1400万美元，主要用于EFZO-FIT™和EFZO-CONNECT™临床试验、efzofitimod生产和研发[8] - 第二季度一般及行政费用为330万美元[8] 合作与人事 - 与斯坦福医学院达成研究协作协议，探索公司抗NRP2抗体在胶质母细胞瘤中的作用[7] - 任命Jayant Aphale博士为技术运营副总裁，负责合同生产和制造、供应链管理等[7]

文章核心观点 - BMEX Gold Inc.终止了之前宣布的非包销私募融资,改为通过上市发行人融资豁免(LIFE)进行新的融资[1][2][3] - 本次融资的最低募集金额为30万加元,最高募集金额为130万加元[2][3] - 本次融资将发行两类单位:非流通单位(NFT单位)和流通单位(FT单位),每单位包括一股普通股和一个认股权证[3] - 本次融资所得资金将用于公司的Dunlop Bay项目勘探和公司的一般及行政开支[6] - 本次融资预计将于2024年8月2日完成,需获得必要批准[7] 公司概况 - BMEX Gold Inc.是一家加拿大初级矿业勘探公司,主要目标是在魁北克省收购、勘探和开发黄金和基本金属项目[9] - 公司目前全力投入其100%拥有的两个项目:King Tut项目和Dunlop Bay项目[9] - 公司股票在多伦多创业板交易,代码为"BMEX",在法兰克福证券交易所交易,代码为"8M0"[10]

| --- | --- | --- | --- | --- | --- | --- | |--------------------|--------------------------|--------------|-------|---------------|--------------|--------| | | June 30, 2024 \nAmount | % of Premium | | 2023 \nAmount | % of Premium | % Chg. | | United American | $ 16,571 | 11 | | $ 14,753 | 11 | 12 | | | | | | | | | | Family Heritage | 36,611 | 35 | | 32,704 | 33 | 12 | | Liberty National | 26,400 | 55 | | 26,208 | 56 | 1 | | American Income | 19,092 | 62 | | 18,169 | 62 | 5 | | Direct to Consumer | 1,814 | ...

1-786-697-3501 Listen live and as a replay at https://investors.globelifeinsurance.com/ under Calls and Meetings Globe Life Inc. is a holding company specializing in life and supplemental health insurance for the middleincome market distributed through multiple channels, including direct to consumer and exclusive and independent agencies. Second Quarter Conference Call Thursday, July 25, 2024 11:00am (Eastern) (Passcode: Globe Life Inc.) MCKINNEY, Texas, July 11, 2024 /PRNewswire/ -- Globe Life Inc. (NYSE: ...

Vancouver, British Columbia--(Newsfile Corp. - June 24, 2024) - Neotech Metals Corp. (CSE: NTMC) (OTC Pink: NTMFF) (FSE: V690) ("Neotech" or the "Company"), is pleased to announce that it intends to complete a non-brokered private placement LIFE financing (the "Offering") for total proceeds of a minimum of $1,500,000 and up to a maximum of $2,500,000, consisting of a minimum of 6,000,000 units of the Company (the "Units") and up to a maximum of 10,000,000 Units at a price of $0.25 per Unit. Each Unit will b ...

According to the complaint, during the class period, Globe Life touted its consistent revenue growth, particularly from AIL, which accounted for 50% of the Company's profits in 2022 and 2023. During the class period, Globe Life reported consistent premium revenue growth at the Company, led by consistent premium revenue growth at AIL. The Company also represented that its employees adhered to a Code of Conduct requiring all Globe Life employees comply with relevant laws and regulations, purportedly ensuring ...

文章核心观点 - 公司已完成非中介私募配售,募集资金将用于公司一般运营资金、现有项目评估和工作 [1][2][3] - 公司总裁表示公司现已处于重新聚焦提升股东价值的位置,期待2024年下半年更加活跃 [3] - 公司在加拿大证券交易所上市,本次配售的证券不受限制 [3] 公司概况 - 公司在北美拥有多个项目,包括内华达州的两个锂项目、安大略省的一个钴项目,以及爱达荷州的两个钴项目 [5] - 公司提醒,临近公司项目的过往发现结果不一定代表公司项目也存在相同矿化 [5] 其他信息 - 公司鼓励投资者加入公司新闻发布名单 [6] - 公司联系方式 [7] - 本新闻稿仅在加拿大发布,不会在美国传播 [8]

. . June 10, 2024 7:00 AM EDT | Source: BMEX Gold Inc The Offering will consist of the sale of a minimum of 2,000,000 non-flow-through units ("NFT Units") at $0.15 per NFT Unit for gross non-flow-through proceeds of $300,000, and will also include a maximum of up to 6,666,667 flow-through units ("FT Unit") at $0.15 per FT Unit for gross flow-through proceeds of up to $1,000,000. Each FT Unit and each NFT Unit consists of one common share (a "Common Share") of the Company and one full common share purchase w ...

NEW ORLEANS, June 05, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the "Class Period"). Long term holders of GL are also encouraged to contact the firm. This action is pending in ...

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-inclass medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our le ...